Rex Bionics widens full-year loss as commercialisation costs rise

Rex Bionics widens full-year loss as commercialisation costs rise
By Fiona Rotherham March 4 (BusinessDesk) - Rex Bionics Plc, the New Zealand company listed on the London Stock Exchange's AIM market, said higher costs to commercialise its robotic exoskeletons widened its full-year loss to 3.56 million pounds from 480,000 pounds a year earlier. The London-based company, whose exoskeletons allows wheelchair-bound people to walk, has changed its reporting date to March 31 from Nov. 30 but has released unaudited results for the 12 months ended Nov. 30 that include, for the first time, the results of its tw...